Lymphoid leukemia
Therapeutic area
Hematology
Rare disease
No
- Definition
- A malignant lymphocytic neoplasm of B-cell or T-cell lineage involving primarily the bone marrow and the peripheral blood. This category includes precursor or acute lymphoblastic leukemias and chronic leukemias.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Lymphoid leukemia
- Therapeutic area
- Hematology
- lymphoid leukemia
- Advanced Lymphoid Leukemia
- leukemia, LYMPHOCYTIC, malignant
- lymphocytic leukemia
- Lymphocytic Leukemia, L1
- Lymphocytic Leukemia, L2
- lymphogenous leukaemia
- lymphogenous leukemia
- lymphoid leukaemia (disease)
- lymphoid leukemia (disease)
- subacute lymphoid leukaemia
- subacute lymphoid leukemia
- Severity
- Severe
- Hematology
- Oncology
Sources for recorded values
- MONDO ID
- MONDO:0005402
- Parent condition
- MONDO:0005059
Related records
Broader conditions (12)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Leukemia
- Lymphoid neoplasm
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (53)
- Acute biphenotypic leukemia
- Acute lymphoblastic leukemia
- Adult acute lymphoblastic leukemia
- Adult T-cell leukemia/lymphoma
- Aggressive NK-cell leukemia
- B acute lymphoblastic leukemia with DUX4 rearrangement
- B acute lymphoblastic leukemia with PAX5 P80R mutation
- B-cell acute lymphoblastic leukemia
- B-cell acute lymphoblastic leukemia with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)
- B-cell adult acute lymphocytic leukemia
- B-cell childhood acute lymphoblastic leukemia
- B-cell chronic lymphocytic leukemia
- B-cell prolymphocytic leukemia
- B-lymphoblastic leukemia with MEF2D rearrangement
- B-lymphoblastic leukemia with MYC rearrangement
- B-lymphoblastic leukemia with NUTM1 rearrangement
- B-lymphoblastic leukemia with PAX5alt
- B-lymphoblastic leukemia with TCF3-HLF fusion
- B-lymphoblastic leukemia with ZNF384 rearrangement
- B-lymphoblastic leukemia/lymphoma MLL rearranged
Trials (2,907)
- "Geriatric Assessment Adapted" Therapy for Ph- ALL Elderly Patients
- "Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
- 2 Gy Total Body Irradiation As Part Of Conditioning Treatment For Patients With Acute Lymphoblastic Leukemia Undergoing CAR T Cell Therapy
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 3-AP and Cytarabine in Treating Patients With Hematologic Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Approved drugs (12)
- Asparaginase
- Blinatumomab
- Clofarabine
- Cytarabine
- Dasatinib anhydrous
- Daunorubicin hydrochloride
- Inotuzumab ozogamicin
- Melphalan hydrochloride
- Mercaptopurine
- Pegaspargase
- Ponatinib
- Ponatinib hydrochloride
Drugs in development (89)
- Acalabrutinib Phase 2
- Alemtuzumab Phase 2
- Alrizomadlin Phase 2
- Alvespimycin hydrochloride Phase 1
- Alvocidib Phase 1
- APG-2575 Phase 2
- Asciminib Phase 1
- Asparaginase erwinia chrysanthemi Phase 1
- Atezolizumab Phase 2
- Azacitidine Phase 2
- Bendamustine hydrochloride Phase 1
- Bevacizumab Phase 2
- Bortezomib Phase 1
- Brexucabtagene autoleucel Phase 2
- Bryostatin 1 Phase 1
- Buparlisib Phase 1
- Calaspargase pegol Phase 1
- Carboplatin Phase 2
- Carvedilol Phase 3
- Cediranib maleate Phase 2